The Week 16 data for ORKA-001 is the primary near-term catalyst. The stock's reaction will depend on efficacy and safety results relative to expectations. Monitor the conference call for details on statistical significance, adverse events, and next development steps.
Price Chart
Executive Summary
Oruka Therapeutics will report Week 16 data for its lead candidate ORKA-001 from the EVERLAST-B Phase 2b trial in plaque psoriasis on October 26, 2026. The data readout is a key catalyst for this clinical-stage biotech with a $5.4B market cap, and the outcome will significantly impact the stock.
Key Facts
- Oruka will announce Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on October 26, 2026.
- The company will host a conference call at 8:00 a.m. ET to discuss the results.
- Oruka is a clinical-stage biotech developing biologics for chronic skin diseases including plaque psoriasis and hidradenitis suppurativa.
Financial Impact
No financial data provided; the data readout is a binary catalyst for the stock.
Risk Factors
- Phase 2b data may not meet efficacy or safety expectations, leading to a significant stock decline.
- The press release does not disclose any results, so the outcome is uncertain until the announcement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387758 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 25, 2026 1d ago | Press Release | $80.15 | awaiting T+5 | — | $80.15 (+0.00%) |
Oct 20, 2026 6d ago | Insider Cluster | $79.92 | awaiting T+5 | — | $80.15 (+0.29%) |
Oct 15, 2026 11d ago | Insider Cluster | $71.93 $80.15 | ▲ +11.43% | ▲ +11.86% | $80.15 (+11.43%) |
Sep 21, 2026 5w ago | Insider Cluster | $94.55 $82.15 | ▲ +13.11% | ▲ +11.93% | $80.15 (+15.23%) |
Sep 15, 2026 5w ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $80.15 (−14.32%) |
Sep 1, 2026 7w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $80.15 (+12.53%) |
Aug 28, 2026 8w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $80.15 (+12.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $80.15 (−29.12%) |
Aug 10, 2026 11w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $80.15 (−23.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers